A recent meta-analysis [70] showed that using EPO, both recombinant and not, would not enhance the risk of side effects (such as thrombocytopenia, hypotension, hepatic adrenal injury); however, in neonates with HIE treated with EPO, there was not a significant reduction in death and neurological impairment. The gene discussed is EPO; the disease is Thrombocytopenia.